Author: Rosenke, Kyle; Hansen, Frederick; Schwarz, Benjamin; Feldmann, Friederike; Haddock, Elaine; Rosenke, Rebecca; Meade-White, Kimberly; Okumura, Atsushi; Leventhal, Shanna; Hawman, David W.; Ricotta, Emily; Bosio, Catharine M.; Saturday, Greg; Feldmann, Heinz; Jarvis, Michael A.
Title: Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model Cord-id: zx3v96lr Document date: 2020_10_8
ID: zx3v96lr
Snippet: The COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we show that MK-4482, an orally administered nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model. The inhibitory effect of MK-4482 on SARS-CoV-2 replication was observed in animals when the drug was administere
Document: The COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we show that MK-4482, an orally administered nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model. The inhibitory effect of MK-4482 on SARS-CoV-2 replication was observed in animals when the drug was administered either beginning 12 hours before or 12 hours following infection in a high-risk exposure model. These data support the potential utility of MK-4482 to control SARS-CoV-2 infection in humans following high-risk exposure as well as for treatment of COVID-19 patients.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date